Introduction {#s1}
============

Temporal and spatial regulation of cell signaling ensures the fidelity of axon pathfinding, which is crucial for nervous system development and function. Multiple signaling pathways coordinate the projection of commissural axons across the CNS (central nervous system) midline, such that the axons are attracted as they approach and enter the midline, but subsequently become repelled in order to exit the midline and to never recross ([@bib18]). Within the spinal commissural axons, Netrin/DCC (Deleted in colorectal carcinoma) signaling is activated to promote midline attraction while SLIT/ROBO (Roundabout) signaling that mediates repulsion is inhibited prior to crossing. Following crossing, SLIT/ROBO signaling becomes upregulated to facilitate midline expulsion and to block midline reentry ([@bib18]).

SLIT/ROBO signaling is evolutionarily conserved and plays an important role in various biological processes, including cell migration, axon guidance, angiogenesis, and organogenesis ([@bib6]). Dysregulation of the SLIT/ROBO pathway has been implicated in several forms of cancer and neurological disorders ([@bib3]; [@bib5]). In both *Drosophila* and vertebrates, control over ROBO repulsion is achieved through multiple mechanisms. In *Drosophila*, Comm blocks ROBO insertion into the axonal surface ([@bib32]; [@bib33]). In vertebrates, PRRG4 (Proline-rich and Gla domain 4) represses ROBO1 surface trafficking, whereas USP33 (Ubiquitin-specific peptidase 33), RabGDI/GDI1 (GDP dissociation inhibitor 1), and CLSTN1 (Calsyntenin1) stabilize or promote ROBO1 surface localization ([@bib1]; [@bib30]; [@bib45]; [@bib57]). In addition, miR-92 has been shown to suppress vertebrate ROBO1 protein translation ([@bib54]). Without affecting ROBO1 protein expression or trafficking, fly *Robo2* and mammalian *Robo3* have been shown to inhibit *Robo1* activity using different mechanisms ([@bib17]; [@bib47]). Mammalian *Robo3* has also been suggested to promote midline crossing by facilitating Netrin/DCC attraction ([@bib58]).

The mammalian *Robo* genes undergo alternative splicing to produce variants with complex expression patterns and guidance activities ([@bib10]; [@bib12]; [@bib13]; [@bib56]). *Robo1* and *Robo2* share a homologous alternative exon 6b, which is 9 and 12 bp in length, respectively. Recent studies demonstrate that alternatively spliced 'microexons' (≤51 bp) are highly conserved in the nervous system and are frequently misregulated in autistic individuals ([@bib27]; [@bib41]). Whether the alternative splicing of microexon 6b in *Robo1* and/or *Robo2* contributes to the dynamic regulation of midline repulsion was until now completely unknown.

Here, we report that the alternative splicing of *Robo1* and *Robo2* (referred to herein as *Robo1/2*) at microexon 6b is crucial for axon guidance and is controlled by the NOVA (Neuro-oncological ventral antigen) family of splicing factors, which are neural-specific KH (hnRNP K homology)-type RNA-binding proteins ([@bib14]). We show that loss of *Nova1 and Nova2* (referred to herein as *Nova1/2*) alters the expression of exon 6b and leads to severe midline crossing and postcrossing guidance defects. Genetically restoring the normal expression profiles of *Robo1/2* exon 6b is able to reverse these defects in *Nova1/2* mutants. Interestingly, exon 6b alternative isoforms display distinct guidance activities and their production is developmentally regulated. Consequently, ROBO-mediated repulsion is not uniformly repressed precrossing as previously believed, but is instead activated initially to block premature crossing and is sufficiently blocked during crossing. Together, our study demonstrates that mammalian ROBO1/2 are subject to complex regulation, which is coordinated by alternative splicing, protein translation and trafficking, and activity inhibition by *Robo3*.

Results {#s2}
=======

Double knockout of *Nova1/2* disrupts midline crossing and postcrossing guidance of spinal commissural axons {#s2-1}
------------------------------------------------------------------------------------------------------------

We reported previously that *Nova1/2* double knockout (dKO) dampens DCC signaling by reducing the full-length *Dcc~long~* isoform while increasing the truncated *Dcc~short~* isoform, which results in delayed commissural neuron migration and axonal projection toward the midline ([@bib40]). As the defect is partial and is somewhat alleviated over time (from E10.5 to E12.5), some *Nova1/2* dKO axons are able to reach the midline at later stages ([@bib40]). We thus further examined midline crossing and postcrossing trajectories of axons in *Nova1/2* dKO embryos using DiI labeling. As subpopulations of axons follow different postcrossing trajectories ([@bib31]), we selected medially located spinal neurons for comparison. At E12.5, we found that approximately half of the axons that had reached the midline failed to cross and turned longitudinally on the ipsilateral side in *Nova1/2* dKO embryos ([Figure 1](#fig1){ref-type="fig"}). In addition, some postcrossing axons projected away from the midline at greater angles in *Nova1/2* dKO mutants than in the wildtype (WT) controls ([Figure 1](#fig1){ref-type="fig"}). Thus, loss of *Nova1/2* causes additional guidance abnormalities in spinal commissural axons in addition to those we reported previously.

![*Nova1/2* double knockout (dKO) disrupts commissural axon midline crossing and postcrossing guidance.\
(**A**) DiI labeling of E12.5 mouse spinal cords in openbook preparations. The top panel shows confocal micrographs of axons at the midline. *Nova1/2* dKO partially blocked midline crossing. Some axons had not yet reached the midline in *Nova1/2* dKO embryos (arrows), consistent with a reduction in DCC-mediated attraction as previously reported ([@bib40]). The bottom panel shows postcrossing axons that projected away from the midline. Some axons projected diagonally (arrow 1) and some projected straight away (arrow 2). In *Nova1/2* dKO embryos, some axons projected diagonally at greater angles from the midline than normal (arrow 3). Dashed lines indicate midline boundaries. Scale bars, 50 μm. (**B**) Quantification of the guidance defects from DiI tracing. Data are shown as the percentage of injection sites with the stated phenotypes. Midline recrossing was not observed in WT or *Nova1/2* dKO embryos. The trajectories of postcrossing axons along the rostrocaudal axis were comparable between WT and *Nova1/2* dKO embryos.\
10.7554/eLife.46042.003Figure 1---source data 1.DiI tracing.](elife-46042-fig1){#fig1}

To determine if failed crossing in *Nova1/2* dKO mutants also results from reduced DCC attraction, we constructed *Dcc; Nova1; Nova2* triple KO mutants. If loss of *Dcc* is fully responsible for the blocked crossing, then the triple KO should cause no more severe defect than *Dcc* single KO. Using anti-ROBO3 to label axons approaching and crossing the midline, we found that *Nova1/2* dKO and *Dcc* single KO embryos exhibited reduced ventral commissures as previously reported ([@bib40]; [@bib53]), and that *Dcc; Nova1; Nova2* triple KO embryos had even thinner commissures than *Dcc* single KO mutants ([Figure 2A,B](#fig2){ref-type="fig"}). This suggests that loss of *Nova1/2* is likely to affect additional guidance signaling besides reducing DCC attraction.

![Midline crossing defect in *Nova1/2* dKO embryos results from elevated ROBO repulsion.\
(**A**) Anti-ROBO3 staining of commissural axons in transverse sections of E11.5 spinal cords. The bottom panel shows closeup images of the floorplate. *Nova1/2* dKO and *Dcc* KO embryos had reduced ventral commissures. *Dcc; Nova1; Nova2* triple KO mutants had even thinner commissures than *Dcc* KO embryos, and some axons appeared to remain on the ipsilateral side without entering the midline (arrow) in the triple KO mutants. In contrast, *Nova1; Nova2; Robo1* triple KO mutants had a slightly increased ventral commissure size compared to *Nova1/2* dKO embryos. Scale bars, 50 μm. (**B**) Quantification of the ventral commissure size in A. Data are normalized to the WT and are represented as the mean ± SD (one-way ANOVA and Bonferroni post test; animal numbers and p values are indicated). (**C**) DiI labeling of E12.5 mouse spinal cords in openbook preparations. In *Nova1/2* dKO embryos, about half of the axons arriving at the midline did not project across. This defect was alleviated by *Robo1* KO. *Nova1/2* dHet and *Robo3* Het, which were phenotypically normal on their own, synergistically blocked midline crossing. Brackets indicate the midline. Scale bar, 50 μm. (**D**) Quantification of midline crossing in C. Data are normalized to the WT and are represented as the mean ± SD (one-way ANOVA and Bonferroni post test; animal numbers and p values are indicated).\
10.7554/eLife.46042.005Figure 2---source data 1.Commissure size and midline crossing.](elife-46042-fig2){#fig2}

Blocked midline crossing has also been reported in *Robo3* KO embryos, where all commissural axons fail to cross and become abnormally sensitive to the SLIT2 repellent in explants ([@bib47]). The crossing defect in *Robo3* KO mutants can be partially rescued by deleting *Robo1/2* together, which allows about half of the axons to cross ([@bib28]). Deleting *Robo1* alone has a mild rescue effect and deleting *Robo2* alone cannot rescue ([@bib28]; [@bib47]). These findings suggest that in the absence of *Robo3*, elevated ROBO1/2 activity can block midline crossing. To determine if elevated ROBO repulsion also blocks crossing in *Nova1/2* dKO embryos, we constructed *Nova1; Nova2; Robo1* triple KO mutants. *Robo1* single KO embryos have a normal commissure size ([@bib28]), and by anti-ROBO3 staining, we found that *Nova1; Nova2; Robo1* triple KO mutants had slightly thicker commissures than *Nova1/2* dKO embryos ([Figure 2A,B](#fig2){ref-type="fig"}). Using DiI labeling, we further examined midline crossing in *Nova1; Nova2; Robo1* triple KO embryos and found that most of the axons that were able to reach the midline were also able to cross ([Figure 2C,D](#fig2){ref-type="fig"}). Thus, the blocked midline crossing in *Nova1/2* dKO embryos is most likely caused by elevated ROBO repulsion.

To understand the genetic relationship between *Nova1/2* and *Robo3* in regulating midline crossing, we constructed triple mutants that are heterozygous (Het) for deletions in all three genes. *Nova1/2* double Het (dHet) or *Robo3* single Het mutants did not exhibit any midline crossing defect ([Figure 2C,D](#fig2){ref-type="fig"}) ([@bib47]). However, the triple Het mutants displayed midline crossing failure as severe as in *Nova1/2* dKO embryos ([Figure 2C,D](#fig2){ref-type="fig"}). Therefore, *Nova1/2* and *Robo3* have a synergistic interaction with regard to repressing midline repulsion and allowing axonal entry.

*Nova1/2* double knockout disrupts *Robo1/2* alternative splicing {#s2-2}
-----------------------------------------------------------------

To determine how NOVA1/2 RNA-binding proteins may control *Robo* genes, we examined *Robo-1, -2, and -3* expression and alternative splicing in *Nova1/2* mutants. We previously reported that *Nova1/2* are both expressed by commissural neurons and their progenitors, and that *Robo3* expression and alternative splicing are not altered by *Nova1/2* dKO ([@bib40]). With respect to *Robo1* and *Robo2*, quantitative RT-PCR and western blotting analyses showed that the total mRNA and protein levels were not altered by *Nova1/2* dKO ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). In addition, quantitative and semi-quantitative RT-PCR showed that most alternative sequences in the promoter and coding regions were not affected; however, the inclusion of microexon 6b in both *Robo1* and *Robo2* was significantly increased in *Nova1/2* dKO embryos ([Figure 3A,B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). The inclusion of exon 6b was sensitive to *Nova1/2* gene copy number ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), which is consistent with the dose-sensitive interaction between NOVAs and their targets ([@bib14]). Similar to the DCC-related guidance defect ([@bib40]), both *Nova1 Het; Nova2 KO* and *Nova1/2* dKO embryos had midline crossing failure, with the defect being more severe in *Nova1/2* dKO animals, whereas the other genotype combinations, including *Nova1/2* dHet mutants, were phenotypically normal. Hereafter, we refer to the *Robo1/2* isoforms that exclude and include exon 6b as e6b- and e6b+, respectively. Exon 6b encodes a short linker between the extracellular third and fourth Ig domains, which is conserved in mammals and chickens ([Figure 3C](#fig3){ref-type="fig"}). The inclusion of the alternative exon 21 in *Robo2*, which encodes an intracellular region between the CC1 and CC2 domains, was somewhat reduced in *Nova1/2* dKO embryos ([Figure 3A,B](#fig3){ref-type="fig"}).

![*Nova1/2* regulate *Robo1/2* alternative splicing.\
(**A**) Alternative splicing of *Robo1/2* exons assessed by semi-quantitative RT-PCR using E11.5 dorsal spinal cord (where commissural neurons are largely located). Schematic shows ROBO1/2 protein domains and the locations of alternatively spliced sequences. Ig, immunoglobulin domain; FN, fibronectin domain; TM, transmembrane domain; CC0-CC3, conserved cytoplasmic domain 0--3. The first Ig domain interacts with SLIT ([@bib43]). (**B**) Quantitative RT-PCR analyses of *Robo*1/2 alternative exons whose expression was altered by *Nova1/2* dKO. Data are normalized to the WT and are represented as the mean ± SD (Student's t-test, two-tailed and unpaired; n = 3 animals; p values are indicated). (**C**) Alignment of peptide sequences encoded by *Robo1/2* exon 6b. Exon 6b encodes a short linker (boxed sequences) between the Ig3 and Ig4 domains. Identical residues are shown in black and non-identical ones in red. *Drosophila* ROBO1 was used for alignment, as it is homologous to both ROBO1 and ROBO2 in vertebrates. (**D**) Splicing assays of *Robo*1/2 exon 6b in COS-1 cells, where a splicing reporter was coexpressed with *Nova1* or *Nova2* and the levels of splice variants were assessed by RT-PCR. Flanking introns of exon 6b in the reporter (in red) contain candidate NOVA-binding sites (7--10 YCAY repeats; Y = C/U; mutations created YAAY repeats; see Materials and methods and [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Alternatively spliced sequences were detected by semi-quantitative RT-PCR using 5' and 3' primers as indicated. Numbers in the electrophoresis images indicate the e6b+ level normalized to the total amount of both isoforms. *Nova1/2* normally repressed the e6b+ levels of both *Robo1* and *Robo2*. Mutating candidate NOVA-binding sites in either flanking intron partially blocked NOVA activity. Eliminating all NOVA-binding sites caused e6b+ to be exclusively expressed.](elife-46042-fig3){#fig3}

Using ex vivo splicing assays, we tested if NOVAs directly regulate *Robo1/2* alternative splicing. We constructed splicing reporters for exon 6b ([Figure 3D](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}; also see Materials and methods) and examined their alternative splicing in COS-1 cells. When an empty expression-control vector was coexpressed with the reporters, two RT-PCR products, corresponding to e6b- and e6b+, were detected. When *Nova1* or *Nova2* was overexpressed, e6b+ was reduced, consistent with the observation that e6b+ was abnormally increased in *Nova1/2* dKO mutants ([Figure 3A,B](#fig3){ref-type="fig"}). When candidate NOVA-binding sites in either intron 6 or intron 6b were mutated from YCAY (Y = C/U) to YAAY ([@bib8]), NOVA-mediated repression of eb6+ was attenuated. Mutations in both introns almost completely blocked NOVAs from reducing e6b+ ([Figure 3D](#fig3){ref-type="fig"}). Thus, NOVAs bind to intron sequences flanking exon 6b and prevent its inclusion into the mRNA product. Using the same approach, we examined NOVA regulation of *Robo2* exon 21. We found that *Nova1* or *Nova2* overexpression did not alter the exon 21 splicing pattern, and that mutating candidate NOVA-binding sites in intron 20 also had no effect ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Thus, NOVAs by themselves do not appear to directly control exon 21 alternative splicing. They may cooperate with or function indirectly through other splicing factors to exert their effect on exon 21.

Restoring *Robo1/2* microexon 6b expression levels rescues *Nova1/2* dKO defects {#s2-3}
--------------------------------------------------------------------------------

To definitively determine if increased inclusion of exon 6b is responsible for the blocked midline crossing in *Nova1/2* dKO embryos, we genetically reduced exon 6b levels by deleting one copy of the exon from the *Robo1*/*2* genomic sequences using the CRISPR/Cas9 technology ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). In the *Nova1/2* dKO background, the WT allele predominantly expressed e6b+ ([Figure 3A](#fig3){ref-type="fig"}; [Figure 4A](#fig4){ref-type="fig"}), whereas the deletion allele only produced e6b- ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). The combination between the WT and deletion alleles generated the two isoforms at a similar ratio to that in the WT at E11.5 ([Figure 4A](#fig4){ref-type="fig"}). Using this approach, we successfully restored the e6b+/e6b- levels of *Robo1* and *Robo2,* either alone or in combination, in *Nova1/2* dKO embryos. Deleting exon 6b in *Robo1* and/or *Robo2* did not alter the total mRNA or protein levels ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}), and did not affect the splicing of the surrounding areas or of other alternative exons ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

![Restoring *Robo1/2* exon 6b levels rescues axon guidance defects in *Nova1/2* dKO embryos.\
(**A**) Alternative splicing of exon 6b in animals with or without the exon 6b deletion allele. Semi-quantitative RT-PCR was performed using RNA from E11.5 dorsal spinal cord. Deleting one copy of exon 6b from *Robo1/2* genomic DNA in *Nova1/2* dKO embryos restored e6b+ expression to a comparable level as in the WT. (**B**) DiI labeling of spinal cord openbooks (top panel) and anti-L1 staining of transverse spinal cord sections (bottom panel) in E12.5 animals with or without exon 6b deletion. As it is difficult to obtain a large number of compound mutants, the rostral half of the spinal cord was used for DiI labeling and the lumbar level was used for anti-L1 staining. Brackets indicate the midline. Arrows indicate the lateral funiculus (LF) and ventral funiculus (VF). Reducing *Robo1(e6b+)* partially rescued both midline crossing and lateral positioning defects in *Nova1/2* dKO embryos, while reducing *Robo2(e6b+)* alone did not rescue. Reducing *Robo1/2(e6b+)* together further rescued both defects. Scale bars, 50 μm. (**C**) Quantification of axon midline crossing and lateral positioning in B. As *Nova* deficiency reduces the number of postcrossing axons due to fewer axons reaching the midline, we compared the ratio between the thickness of the lateral and ventral funiculi within the same section. Data are represented as the mean ± SD (one-way ANOVA and Bonferroni post test; animal numbers and p values are indicated; ns, not significant).\
10.7554/eLife.46042.012Figure 4---source data 1.Phenotypic rescues by exon 6b deletion.](elife-46042-fig4){#fig4}

Using DiI labeling, we found that reducing *Robo1(e6b+)* alone partially restored midline crossing in *Nova1/2* dKO mutants, whereas reducing *Robo2(e6b+)* alone had no effect ([Figure 4B,C](#fig4){ref-type="fig"}). Reducing both *Robo1(e6b+)* and *Robo2(e6b+)* together further rescued the midline crossing defect ([Figure 4B,C](#fig4){ref-type="fig"}).

After crossing the midline, commissural axons join longitudinal tracts that traverse parallel to the floorplate at different dorso-ventral positions. SLIT/ROBO signaling has been shown to direct the lateral positioning of longitudinal axons ([@bib20]; [@bib28]; [@bib34]; [@bib42]). In *Nova1/2* dKO embryos, we found that some DiI-labeled postcrossing axons steered away from the midline at abnormally larger angles, raising the possibility of abnormal lateral positioning ([Figure 1](#fig1){ref-type="fig"}). As DiI traced only a subset of axons, we used the anti-L1 marker that labels all postcrossing commissural axons as well as ipsilateral-projecting axons to further assess the dorso-ventral positioning, as previously described ([@bib28]). As there are fewer postcrossing axons in *Nova1/2* dKO embryos due to fewer axons reaching the midline, we compared the ratio between the ventral and lateral funiculi within the same section to determine the relative distribution of longitudinal axons. We found that the ventral tract close to the midline was reduced, whereas the lateral tract was enlarged in *Nova1/2* dKO spinal cords ([Figure 4B,C](#fig4){ref-type="fig"}), suggesting that some longitudinal axons projected further away from the midline. We also found that reducing *Robo1(e6b+)* alone in *Nova1/2* dKO embryos partially reversed this defect, whereas reducing *Robo2(e6b+)* alone had no effect ([Figure 4B,C](#fig4){ref-type="fig"}). Reducing both *Robo1(e6b+)* and *Robo2(e6b+)* largely rescued the defect ([Figure 4B,C](#fig4){ref-type="fig"}). The same degree of rescue was also observed in anti-ROBO1 labeled longitudinal axons ([Figure 4---figure supplement 2A,B](#fig4s2){ref-type="fig"}). Anti-ROBO2 staining was not used to assess the phenotype as ROBO2 is primarily expressed by axons in the lateral funiculi ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). The overall patterns of ROBO1/2 expression, which are low on precrossing axons and are highly upregulated on postcrossing axons, were comparable between WT and *Nova1/2* dKO embryos ([Figure 4---figure supplement 2A,C](#fig4s2){ref-type="fig"}).

Netrin/DCC signaling has been shown to control postcrossing commissural axon trajectories in the hindbrain, but not in the spinal cord. In *Netrin1* or *Dcc* KO mutants, hindbrain commissural axons project at larger angles away from the midline, whereas spinal commissural axons have normal postcrossing projection ([@bib49]). To investigate whether the lateral positioning defect in *Nova1/2* mutants can result from impaired DCC signaling, we examined anti-L1 staining in *Dcc; Nova1; Nova2* triple KO spinal cords. *Dcc* KO mutants had a slight increase in the lateral funiculi, which was much less severe than in *Nova1/2* dKO embryos ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In *Dcc* KO embryos, some lateral axons evaded the medial spinal cord, which could result from axon defasiculation and/or from a lack of restrictive signal from the medial spinal cord. Defasiculation is observed in precrossing axons in *Dcc* KO, but not in *Nova1/2* dKO embryos ([@bib40]; [@bib53]), possibly due to the fact that DCC~short~ is still present in *Nova1/2* dKO mutants, which may be sufficient for axonal adhesion. In *Dcc; Nova1; Nova2* triple KO embryos, the lateral funiculi were enlarged and most lateral axons projected into the medial spinal cord. Thus, the defects in the triple KO mutants appear to be a combination of those seen in *Dcc* and *Nova1/2* KO mutants. Taken together, the lateral positioning defect in *Nova1/2* dKO embryos cannot result solely from a deficiency in DCC signaling, although loss of *Dcc* may contribute to a small degree.

Microexon 6b splice variants of ROBO1/2 have distinct guidance activities {#s2-4}
-------------------------------------------------------------------------

To distinguish between the in vivo activities of e6b- and e6b+, we compared the effects of ectopically expressing the isoforms in chicken embryos. We found that *Robo1(e6b-)* expression partially blocked midline crossing, with \~30% of the axons failing to cross. *Robo1(e6b+)* further blocked midline crossing, with \~49% of the axons being unable to cross ([Figure 5A,B](#fig5){ref-type="fig"}). Thus, e6b+ appears to have a stronger repulsive effect than e6b-. We also overexpressed the *Robo1* isoforms in cultured mouse embryos. In *Robo3* Het embryos, which were used to lower the inhibition of exogenously expressed mouse *Robo1* cDNA and thus to potentiate the effect, we observed significant midline crossing defects ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). *Robo1(e6b+)* overexpression blocked about half of the axons from crossing the midline, whereas *Robo1(e6b-)* overexpression caused a milder defect ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), consistent with their effects in chickens.

![ROBO1/2 splice variants have distinct guidance activities.\
(**A**) Openbook preparations of chicken spinal cords electroporated with *Actb-gfp* or with different *Robo1* or *Robo2* isoforms. Transfected neuronal cell bodies are oriented to the left, and the rostral end of the spinal cord is pointing up. Brackets indicate the midline. Arrowheads indicate the medial and lateral positions of postcrossing axons. Distance one is between the midline and the dorsolateral-most longitudinal axons and distance two is the total height of the spinal cord. Scale bar, 50 μm. (**B**) Quantification of midline crossing and lateral positioning of commissural axons in A. Lateral positioning is quantified as the ratio between distances one and two. Data are represented as the mean ± SD (one-way ANOVA and Bonferroni post test; animal numbers and p values are indicated; ns, not significant). (**C**) Immunohistochemistry of transverse sections of chicken spinal cords electroporated with HA-tagged *Robo1* isoforms. Scale bar, 50 μm. (**D**) Western blotting analysis of lysates from chick spinal cords electroporated with HA-tagged *Robo1/2* isoforms.\
10.7554/eLife.46042.015Figure 5---source data 1.Overexpression of *Robo1/2 *isoforms.](elife-46042-fig5){#fig5}

In addition, *Robo1(e6b-)* ectopic expression in chicken embryos directed commissural axons that had reached the contralateral side or abnormally stayed on the ipsilateral side to travel closely to the midline within the ventral funiculi ([Figure 5A,B](#fig5){ref-type="fig"}). In contrast, *Robo1(e6b+)* ectopic expression guided axons further away from the midline to a more dorsolateral position than normal ([Figure 5A,B](#fig5){ref-type="fig"}). Thus, *Robo1*(*e6b-)* and *Robo1*(*e6b+)* have distinct activities in guiding postcrossing commissural axons. Using anti-L1 staining, we also examined the positioning of longitudinal axons in homozygous exon 6b deletion mice, and found that *Robo1* e6bΔ/Δ embryos, which produced exclusively e6b- ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}), had enlarged ventral funiculi ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), consistent with the observation that e6b- directed axons close to the midline in chickens ([Figure 5A,B](#fig5){ref-type="fig"}).

As both exons 6b and 21 of *Robo2* were affected by *Nova1/2* dKO, we cloned cDNAs with all four combinations between the exons and tested their activities in chicken embryos. We found that ectopic expression of *Robo2(e6b-; e21-)* did not affect midline crossing ([Figure 5A,B](#fig5){ref-type="fig"}). In contrast, expression of *Robo2(e6b+; e21-)*, *Robo2(e6b-; e21+)*, or *Robo2(e6b+; e21+)* similarly blocked about half of the axons from crossing ([Figure 5A,B](#fig5){ref-type="fig"}). Thus, the inclusion of four amino acids in the extracellular domain from exon 6b or the inclusion of 42 amino acids in the intracellular domain from exon 21 similarly increases ROBO2 repulsion. The effects of these exon inclusions are neither synergistic nor additive. Taken together, in the absence of the exon 21 coding sequence, e6b+ appears to be more repulsive than e6b-. In the presence of exon 21, e6b- and e6b+ are comparable in their activities.

Ectopic expression of all *Robo2* isoforms directed postcrossing axons to comparable lateral positions as in GFP-expressing controls ([Figure 5A,B](#fig5){ref-type="fig"}), indicating similar activities among ROBO2 variants in guiding longitudinal axons. Consistent with these findings, *Robo2* e6bΔ/Δ homozygous mutants had normal dorso-ventral positioning of longitudinal tracts ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

Using immunohistochemistry and western blotting, we found that the electroporated *Robo1/2* isoforms were expressed at comparable levels in chicken embryos and that the exogenously expressed receptors could be detected on both pre- and post-crossing axons ([Figure 5C,D](#fig5){ref-type="fig"}).

Microexon 6b splice variants of ROBO1/2 have distinct signaling properties {#s2-5}
--------------------------------------------------------------------------

Using cell surface biotinylation assays, we found that the ROBO1 or ROBO2 isoforms were inserted into the surface of COS-1 cells at comparable levels ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). We then compared the binding between the ROBO variants with an AP-SLIT2 (N-term) fusion protein in COS-1 cells. We found that the ROBO1 or ROBO2 isoforms had comparable binding affinities toward SLIT2 (N-term) ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), consistent with the fact that the isoforms share the same SLIT-binding domain ([Figure 3A](#fig3){ref-type="fig"}) ([@bib43]).

The RHO family of small GTPases have been shown to mediate SLIT/ROBO signaling during cell migration and axon guidance ([@bib4]). Activation of the SLIT/ROBO pathway inhibits CDC42, activates RAC1, and has distinct effects on RHOA in different cell types ([@bib19]; [@bib23]; [@bib52]; [@bib55]). Using small GTPase activation assays, we compared the downstream signaling of the ROBO1/2 isoforms. We found that both ROBO1 isoforms inhibited CDC42 and activated RAC1, with e6b+ exerting a stronger effect than e6b- ([Figure 6](#fig6){ref-type="fig"}). Among the four ROBO2 isoforms, e6b-; e21- had no effect on either CDC42 or RAC1, while the other three similarly inhibited CDC42 and activated RAC1 ([Figure 6](#fig6){ref-type="fig"}). We did not observe significant changes in RHOA activation in the COS-1 cells expressing any of the isoforms upon SLIT2 N-term stimulation. Taken together, *Robo2(e6b-;e21-)*, the only isoform that does not block midline crossing when ectopically expressed ([Figure 5](#fig5){ref-type="fig"}), has no effect on CDC42/RAC1 ([Figure 6](#fig6){ref-type="fig"}). By contrast, other ROBO1/2 isoforms inhibit CDC42 and activate RAC1 following SLIT2 binding. Between the ROBO1 isoforms, e6b+ has a stronger effect than e6b-.

![ROBO1/2 splice variants have distinct signaling activities.\
(**A**) Regulation of CDC42/RAC1 activation by ROBO1/2 isoforms in COS-1 cells. SLIT2 N-term was added at 500 ng/ml for 10 min at 37°C. GTP-bound/activated CDC42 or RAC1 was pulled down by PAK-GST beads and detected by western blotting. (**B**) Data from three independent assays showing fold changes in CDC42/RAC1 activation upon SLIT2 N-term stimulation, represented as the mean ± SD.\
10.7554/eLife.46042.018Figure 6---source data 1.Activation of small GTPases by ROBO1/2 isoforms.](elife-46042-fig6){#fig6}

Microexon 6b alternative splicing is developmentally controlled and is important for proper timing of midline crossing {#s2-6}
----------------------------------------------------------------------------------------------------------------------

Using rat embryos to enable separation of the dorsal and ventral halves of the spinal cord, we examined *Robo1/2* exon 6b alternative splicing and *Nova1/2* expression in commissural neurons (predominantly in the dorsal half) over developmental stages. In rats, neurogenesis in the dorsal spinal cord starts around E11, and midline crossing is almost complete by E14 (the equivalent stages are E9.5 to E12.5 in mice). We found that *Robo1/2(e6b+)* was the predominant form at E11, and that over time, *Robo1/2(e6b+)* decreased while *Robo1/2(e6b-)* increased ([Figure 7A](#fig7){ref-type="fig"}). The switch in the e6b isoform levels coincided with a steady increase in *Nova1/2* expression over this period ([Figure 7B](#fig7){ref-type="fig"}), which represses e6b+ production ([Figure 3D](#fig3){ref-type="fig"}).

![Alternative splicing of *Robo1/2* is developmentally regulated to ensure proper timing of midline crossing.\
(**A,B**) The expression levels of *Robo1/2* exon 6b and *Nova1/2*, respectively, in dorsal spinal cord from E11 to E14 rats (equivalent of E9.5 to E12.5 in mice), as measured by RT-PCR. Rat embryos were used to allow separation of the dorsal and ventral halves of the spinal cord. (**C**) Anti-ROBO3 staining of transverse sections of WT and *Robo* e6bΔ/Δ spinal cords at E10.5 lumbar (top) and brachial (bottom) levels. Arrowheads indicate the ventral commissure consisting of midline-crossing axons. The ventral commissures in *Robo1* e6bΔ/Δ and *Robo1/2* e6bΔ/Δ mutants were thicker than in the WT controls at the lumbar level. All genotypes had comparable ventral commissure thickness at the brachial level. Scale bar, 50 μm. (**D**) Quantification of the ventral commissure size in C. Data are represented as the mean ± SD (one-way ANOVA and Bonferroni post test; animal numbers and p values are indicated; ns, not significant).\
10.7554/eLife.46042.021Figure 7---source data 1.Early projection of commissural axons in exon 6b deletion mutants.](elife-46042-fig7){#fig7}

Since the predominant expression of *Robo1/2(e6b+)* in *Nova1/2* dKO embryos blocked midline crossing despite the presence of other inhibitory factors of ROBO1/2 ([Figure 4](#fig4){ref-type="fig"}), we wondered if the expression of e6b+ during early development would help prevent premature midline crossing by commissural axons. Using anti-ROBO3 staining, we followed early projection of commissural axons at the lumbar level of E10.5 spinal cord, where and when many commissural axons had not yet reached the floor plate and appeared to be unfasciculated ([Figure 7C](#fig7){ref-type="fig"}). The size of the ventral commissure was small ([Figure 7D](#fig7){ref-type="fig"}). By contrast, in *Robo1* e6bΔ/Δ mutants lacking e6b+, the ventral commissure was much thicker and commissural axons were mostly fasciculated ([Figure 7C,D](#fig7){ref-type="fig"}). This suggests that a larger number of axons had reached and crossed the midline in the mutants than in the WT controls. We also found that *Robo2* e6bΔ/Δ mutants were indistinguishable from the WT, whereas *Robo1/2* e6bΔ/Δ double mutants displayed a similar phenotype to that in *Robo1* e6bΔ/Δ single mutants ([Figure 7C,D](#fig7){ref-type="fig"}). Thus, *Robo1(e6b+)*, but not *Robo2(e6b+),* appears to prevent premature midline crossing by commissural axons. To ensure that the mutant and WT embryos were comparable in their overall development, we examined embryos from multiple litters and selected embryos of similar sizes. As TAG1 expression by motor, commissural, and dorsal root ganglion (DRG) neurons is developmentally controlled and transient ([@bib16]) ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), we also used anti-TAG1 staining to ensure that the WT and mutant spinal cords were of a comparable developmental stage ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}).

At the brachial level of E10.5 spinal cord, where neuronal development proceeds further than at the lumbar level, additional commissural axons were found to have crossed the midline based on anti-ROBO3 staining ([Figure 7C](#fig7){ref-type="fig"}). All exon 6b deletion mutants became indistinguishable from the WT controls with regard to the size of the ventral commissure ([Figure 7C](#fig7){ref-type="fig"}). Thus, the lack of *Robo1(e6b+)* allows commissural axons to cross the midline earlier, but does not permit additional axons to cross.

Discussion {#s3}
==========

During the initial projection of commissural axons, Netrin/DCC signaling promotes axonal outgrowth and attraction toward the midline. Meanwhile, ROBO1/2 are inhibited by a number of factors and consequently the axons are believed to be nonresponsive to the SLIT family of midline repellents ([Figure 8](#fig8){ref-type="fig"}). Our previous study shows that NOVAs modulate DCC activity by regulating the production of two distinct splice variants, DCC~long~ and DCC~short~ ([@bib40]). In *Nova1/2* dKO embryos, where DCC~long~ is reduced, fewer axons are able to reach the midline, similar to in *Dcc* KO embryos ([Figure 8](#fig8){ref-type="fig"}). In this study, we report that NOVAs also control midline repulsion by regulating the temporal production of two *Robo1/2* isoforms, e6b+ and e6b-. The ROBO1/2(e6b+) and ROBO1/2(e6b-) receptors have minute sequence variations yet display distinct activities, with e6b+ being more repulsive than e6b- ([Figure 5A,B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). *Robo1/2(e6b+)* is initially predominantly expressed in spinal commissural neurons. Over development, as *Nova1/2* levels increase in spinal commissural neurons, e6b+ expression is reduced while e6b- expression is elevated ([Figure 7A,B](#fig7){ref-type="fig"}; [Figure 8](#fig8){ref-type="fig"}). Consequently, we found that ROBO1/2 repulsion is not uniformly inhibited precrossing. Instead, when e6b+ is predominantly expressed early on, commissural axons are sensitive to SLIT, because loss of e6b+ in *Robo1* e6bΔ/Δ mutants allows the axons to cross the midline precociously ([Figure 7C,D](#fig7){ref-type="fig"}). Later on, in order for axons to enter the midline, ROBO1/2 repulsion must be attenuated and sufficiently inhibited, as the persistence of e6b+ as the predominant variant in *Nova1/2* dKO embryos blocks midline crossing in some axons ([Figure 4](#fig4){ref-type="fig"}; [Figure 8](#fig8){ref-type="fig"}). Thus, besides being predominantly attracted by Netrin, precrossing axons are also somewhat repelled by SLIT to ensure proper timing in approaching and crossing the midline. A balance between Netrin and SLIT signaling systems has been implicated in other guidance events, such as in positioning spinal motor neuron cell bodies and in guiding longitudinal axons in the midbrain ([@bib36]; [@bib35]).

![Model of NOVA1/2 regulation of commissural axon guidance.\
As commissural axons approach and enter the midline, Netrin/DCC signaling promotes axonal outgrowth and midline attraction. *Nova1/2* regulate *Dcc* alternative splicing by promoting the production of the full-length *Dcc~long~* isoform. In *Nova1/2* dKO embryos, *Dcc~long~* is reduced and fewer axons are able to reach the midline, phenocopying *Dcc* KO mutants. In precrossing axons, SLIT/ROBO repulsion is repressed by multiple genes including *Prrg4*, *miR-92*, and *Robo3* to allow midline entry. We show here that ROBO repulsion is not uniformly repressed precrossing, but is developmentally controlled such that ROBO repulsion is active early on to prevent premature crossing and is sufficiently inhibited later to allow crossing. This is achieved through the regulation of *Robo1/2* alternative splicing at microexon 6b by the NOVA splicing factors. As NOVAs increase during development, the *Robo1/2(e6b+)* isoform, which has a greater repulsive activity, is reduced, whereas the *Robo1/2(e6b-)* isoform is upregulated. In *Nova1/2* dKO embryos, e6b+ is abnormally elevated and the axons that are able to reach the midline often fail to enter. A similar and more complete defect is present in *Robo3* KO embryos and partial loss of function in *Robo3* and *Nova1/2* synergistically blocks midline entry. Upon entering the midline, SLIT/ROBO repulsion is upregulated, which facilitates axonal exit, blocks recrossing, and guides postcrossing axons to appropriate lateral positions. *Robo1(e6b-)* directs the axons medially, while *Robo1(e6b+)* and *Robo2* guide the axons dorsolaterally. Double knockout of *Nova1/2* reduces the medial tract and increases the dorsolateral tract.](elife-46042-fig8){#fig8}

Taken together, the defects in midline crossing in *Nova1/2* dKO mutants are twofold. First, the deficiency in Netrin/DCC attraction causes fewer axons to reach the midline. Second, elevated SLIT/ROBO repulsion partially blocks axons from entering once they arrive at the midline ([Figure 8](#fig8){ref-type="fig"}). Although elevated ROBO repulsion may also prevent some axons from getting to the midline, the fact that restoring *Dcc~long~* expression in *Nova1/2* dKO embryos almost completely reverses the defect argues that ROBO repulsion does not play a major role ([@bib40]). Consistent with this notion, overexpression of ROBO3.1, which represses ROBO1/2-mediated repulsion, is not sufficient to restore axonal outgrowth and projection to the midline in *Nova1/2* dKO embryos ([@bib40]). Similarly, dampened DCC attraction may also block some axons from entering the midline. However, the fact that reducing *Robo1/2(e6b+)* levels largely enables crossing in *Nova1/2* dKO embryos argues against a major contribution by DCC misregulation. Thus, NOVAs regulate both midline attraction and repulsion by controlling the alternative splicing of two groups of key guidance receptors, DCC and ROBO1/2. Consistent with our findings in the spinal commissural neurons, *Dcc* and *Robo2* alternative splicing has been reported to be disrupted in the same manner in E18.5 *Nova2* KO cortex ([@bib48]). *Nova2* KO mutants are missing the corpus callosum, a major brain commissure, and restoring *Dcc~long~* expression in *Nova2* KO cortex alone is not sufficient to rescue midline crossing by callosal axons ([@bib48]). Our results suggest that restoring the normal *Dcc~long~* level and simultaneously reducing *Robo1* and/or *Robo2* e6b+ expression are likely to be required to rescue the acallosal phenotype.

Given that *Nova1/2* dKO does not significantly alter the overall levels and patterns of *Robo1/2* expression, it is likely that the ROBO1/2 isoforms are subject to similar repression in their translation and/or trafficking, such as by mir-92 and PRRG4 ([@bib30]; [@bib54]). As overexpressing either e6b isoform results in the presence of the receptors on precrossing axons and blocks crossing ([Figure 5](#fig5){ref-type="fig"}), downregulating both isoforms will be crucial to inhibiting midline repulsion. Due to a lack of specific antibodies to distinguish between the endogenous ROBO1/2 isoforms and the fact that ectopic expression alters the normal protein distributions, we could not directly test if the different ROBO1/2 isoforms are similarly inserted into the axonal surface in vivo ([Figure 5C](#fig5){ref-type="fig"}). Without affecting ROBO1/2 levels or localizations, both *Robo3* and *Nova1/2* inhibit ROBO1/2 receptor activities. The mechanism underlying ROBO3-mediated inhibition remains unknown, and NOVAs repress the production of the e6b+ variant with a higher repulsive activity ([Figure 3D](#fig3){ref-type="fig"}; [Figure 5](#fig5){ref-type="fig"}). Partial loss of function in *Nova1/2* and *Robo3,* which somewhat increases *Robo1/2(e6b+)* expression ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) and reduces *Robo1/2* inhibition, respectively, can synergistically block midline crossing ([Figure 2C,D](#fig2){ref-type="fig"}). Taken together, repressing ROBO1/2 precrossing involves the collaboration of multiple mechanisms, and the microexon 6b isoforms are likely to be regulated by all the factors, although there may be some quantitative differences. The temporal regulation of exon 6b by NOVAs remains to be further examined at the protein level and at single-neuron resolution, and we cannot yet distinguish if it plays an instructive or a permissive role in midline crossing.

Given that deleting *Robo1(e6b+)*, but not *Robo2(e6b+),* allows premature midline crossing, *Robo1*-expressing axons are likely to be pioneer axons that initiate midline crossing. *Robo2*-expressing axons, by contrast, may cross by following an existing axonal scaffold. The leader and follower commissural axons have been demonstrated to have distinct growth cone morphology and growth kinetics during midline crossing ([@bib2]). This hypothesis may help to explain why *Robo2* deletion alone cannot promote midline crossing in *Robo3* KO mutants, but can help facilitate crossing when *Robo1* is also deleted to allow some axons to cross first ([@bib28]). In this study, we similarly observed that *Robo2(e6b+)* reduction alone cannot rescue the midline crossing deficit in *Nova1/2* dKO embryos, but can rescue the defect when combined with *Robo1(e6b+)* reduction ([Figure 4](#fig4){ref-type="fig"}).

Once axons reach the contralateral side, ROBO repulsion becomes upregulated. ROBO3.1 and mir-92 have been shown to be absent on postcrossing axons ([@bib10]; [@bib54]), and factors including USP33, RabGDI, and CLSTN1 stabilize or promote ROBO1 surface level postcrossing ([@bib1]; [@bib45]; [@bib57]). High ROBO repulsion thus facilitates midline exit, blocks reentry, and guides postcrossing axons away from the midline ([Figure 8](#fig8){ref-type="fig"}). Previous studies have shown that *Robo1* directs longitudinally projecting axons close to the midline, whereas *Robo2* guides them more dorsolaterally ([@bib20]; [@bib28]). We show here that distinct ROBO1 isoforms help position axons in both tracts, with *Robo1(e6b-)* directing axons to the medial position and *Robo1(e6b+)* guiding them more laterally ([Figure 5](#fig5){ref-type="fig"}). In *Nova1/2* dKO embryos, more axons join the dorsolateral tract and reducing *Robo1/2(e6b+)* expression can rescue the defect ([Figure 4](#fig4){ref-type="fig"}). By contrast, in the absence of *Robo1(e6b+)*, as in *Robo1* e6bΔ/Δ embryos, more axons join the medial tract ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). The lateral funiculi are still present in *Robo1* e6bΔ/Δ embryos, suggesting that *Robo2* activity is sufficient to direct the axons laterally, consistent with previous findings ([@bib20]; [@bib28]).

It is important to note that within different commissural neuron populations, DCC and ROBO1/2 can have distinct guidance activities. For example, the ventral-most spinal commissural neurons do not require Netrin to project toward the midline ([@bib46]). In the hindbrain, Netrin/DCC signaling is not required to attract commissural axons toward the midline, but it instead attracts postcrossing axons close to the midline. In these hindbrain commissural axons, ROBO1/2 are important for expelling axons out of the midline, but are not involved in their postcrossing projection ([@bib49]). The available tools for our analyses, including DiI and axonal markers (e.g. anti-ROBO3 and anti-L1), did not allow us to distinguish between specific subgroups of commissural axons.

As SLIT/ROBO signaling is only partially responsible for midline repulsion, additional guidance pathways, including Ephrin/Eph, Semaphorin/Neuropilin/Plexin, and Slit2(C-term)/PlexinA1 are in play ([@bib15]; [@bib37]; [@bib60]). Many of these guidance molecules have been reported to have splice variants ([@bib9]; [@bib24]; [@bib38]; [@bib50]; [@bib51]). Therefore, it is possible that additional alternative splicing events are involved in regulating commissural axon guidance at the midline. In fact, from our previous RNAi screen against RNA-binding proteins, we have identified additional splicing regulators with midline crossing defects ([@bib40]), underscoring the general importance of alternative splicing in regulating axon guidance.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                 Designation                         Source or\                             Identifiers     Additional\
  or resource                                                                 reference                                              information
  --------------------------------------- ----------------------------------- -------------------------------------- --------------- -----------------------------------------------------------------------------------------------
  Genetic reagent (*Mus musculus*)        CD-1                                Charles River Laboratories             Crl:CD-1(ICR)   

  Genetic reagent (*Mus musculus*)        *Dcc* knockout                      [@bib21]                                               

  Genetic reagent (*Mus musculus*)        *Nova1* knockout                    [@bib29]                                               

  Genetic reagent (*Mus musculus*)        *Nova2* knockout                    [@bib48]                                               

  Genetic reagent (*Mus musculus*)        *Robo1* knockout                    [@bib42]                                               

  Genetic reagent (*Mus musculus*)        *Robo3* knockout                    [@bib47]                                               

  Genetic reagent (*Mus musculus*)        *Robo1* e6b del                     This paper                                             [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}

  Genetic reagent (*Mus musculus*)        *Robo2* e6b del                     This paper                                             [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}

  Genetic reagent (*Mus musculus*)        *Robo1; Robo2* e6b del              This paper                                             [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}

  Genetic reagent (*Gallus gallus*)       Chicken embryos                     Charles River Laboratories             10100326        Specific pathogen-free fertile eggs

  Genetic reagent (*Rattus norvegicus*)   Sprague Dawley rats                 Charles River Laboratories             Crl:SD          

  Cell line (*Cercopithecus aethiops*)    COS-1                               American Type Culture Collection       CRL-1650        Free of mycoplasma contamination

  Recombinant DNA reagent                 *Robo1 (e6b-)*                      This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo1 (e6b+)*                      This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo2 (e6b-; e21-)*                This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo2 (e6b-; e21+)*                This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo2 (e6b+; e21-)*                This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo2 (e6b+; e21+)*                This paper                                             HA tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Robo1* exon 6b splicing reporter   This paper                                             [Figure 3](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}

  Recombinant DNA reagent                 *Robo2* exon 6b splicing reporter   This paper                                             [Figure 3](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}

  Recombinant DNA reagent                 *Nova1-V5*                          [@bib40]                                               V5 tag at C-term; pCAGGS vector

  Recombinant DNA reagent                 *Nova2-V5*                          [@bib40]                                               V5 tag at C-term; pCAGGS vector

  Antibody                                ROBO3 rabbit polyclonal             [@bib47]                                               IHC (1:1000)

  Antibody                                L1 rat monoclonal                   MilliporeSigma                         MAB5272         IHC (1:1000)

  Antibody                                ROBO1 rabbit polyclonal             Novus Biologicals                      NBP2-20195      IHC (1:1000); Western blot (1:500)

  Antibody                                ROBO2 rabbit polyclonal             Novus Biologicals                      NBP1-81399      IHC (1:1000)

  Antibody                                ROBO2 mouse monoclonal              R and D Systems                        MAB3147         Western blot (1:500)

  Antibody                                TAG1 mouse monoclonal IgM           Developmental Studies Hybridoma Bank   4D7             IHC (1:1000)

  Antibody                                HA rat monoclonal                   Roche                                  3F10            IHC (1:1000); Western blotting (1:1000, HRP conjugated)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Dcc, Nova1*, *Nova2*, *Robo1*, and *Robo3* KO mutants were generated and characterized previously ([@bib21]; [@bib29]; [@bib42]; [@bib47]; [@bib48]). All mouse strains were outcrossed to the CD-1 mouse strain. Heterozygous animals were interbred to generate WT and KO animals. Timed pregnant Sprague Dawley rats were purchased from Charles River to obtain embryos of different developmental stages.

CRISPR/Cas9 knockout mice {#s4-2}
-------------------------

*Robo1* e6bΔ*, Robo2* e6bΔ, and *Robo1* e6bΔ; *Robo2* e6bΔ mutants were generated using the CRISPR/Cas9 technology ([@bib26]). Single guide RNAs were selected using tools developed by the Zhang laboratory at MIT (website crispr.mit.edu; algorithm described in [@bib25]). *Cas9* mRNA and single guide RNA were in vitro transcribed using mMESSAGE mMACHINE T7 kit and MEGAshortscript T7 kit (Thermo Fisher Scientific), respectively. RNA products were purified using MEGAclear kit (Thermo Fisher Scientific) following the manufacturer's protocol. RNAs were injected into pronuclei at 100 ng/μl for *Cas9* mRNA and at 25 ng/μl for each single guide RNA. Two guide RNAs that flank exon 6b were injected to introduce genomic DNA deletions in *Robo1* or *Robo2* alone. Simultaneous injection of four guide RNAs was used to delete exons 6b from both *Robo1* and *Robo2*. Animals harboring desired deletions were selected by genomic DNA PCR reactions and confirmed by Sanger sequencing. Mutant mice were outcrossed to CD-1 mice and were used to breed with *Nova1/2* dKO mice to generate compound mutants. Homozygous *Robo1/2* exon 6b deletion mutants are viable and fertile.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Single guide RNAs used to generate exon 6b deletions in *Robo1/2* (also see [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}).                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- -----------------------------------
  *Robo1* e6bΔ                                                                                                                               Intron6: GAGTCTTGAAATCGATACTAtgg (PAM sequence in lower case)\   \-
                                                                                                                                             Intron6b:\                                                       
                                                                                                                                             ACTGCACAGAATAAATCTGCagg                                          

  *Robo2* e6bΔ                                                                                                                               \-                                                               Intron6: TCATAATTCAGTTATGAATAagg\
                                                                                                                                                                                                              Intron6b:\
                                                                                                                                                                                                              ACTAAAGCGACCGAAAAGCCagg

  *Robo1* e6bΔ; *Robo2* e6bΔ                                                                                                                 Intron6: GAGTCTTGAAATCGATACTAtgg\                                Intron6: CTGTAGACATTACAATGGTGtgg\
                                                                                                                                             Intron6b:\                                                       Intron6b:\
                                                                                                                                             ACTGCACAGAATAAATCTGCagg                                          ACTAAAGCGACCGAAAAGCCagg
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cDNAs {#s4-3}
-----

Total RNA was isolated from E11.5 CD-1 mouse spinal cord, and *Robo1/2* cDNAs were cloned by RT-PCR and confirmed by Sanger sequencing. For alternatively spliced sequences in *Robo1/2* that were not affected by *Nova1/2* dKO, the most abundant variant was used for the cDNAs. An HA tag was added to the C-terminus to help detect protein expression. *Nova* cDNAs used in the splicing assays were previously described ([@bib40]).

Alternative exon numbering {#s4-4}
--------------------------

Exon numbers were designated using NCBI reference sequences NM_019413.2 for *Robo1* and NM_175549.4 for *Robo2.* Exon 6b from either gene is not included in the reference sequence and is located between exons 6 and 7 of the reference sequence.

DiI tracing {#s4-5}
-----------

DiI labeling of spinal commissural axons was carried out as previously described ([@bib10]). E12.5 spinal cords were dissected and fixed with 4% paraformaldehyde (PFA). Vybrant DiI cell-labeling solution (Thermo Fisher Scientific) was microinjected into one side of the spinal cord at mediolateral positions. Spinal cords were incubated overnight at 37°C in 1xPBS, prepared in an openbook configuration, and imaged with fluorescence microscopy.

For confocal microscopy, images of openbook spinal cord preparations were acquired on a Zeiss 510 LSM confocal microscope using ZEN imaging software. For each image, 20--24 3.0 μm thick optical sections were acquired. Maximum intensity Z-projections were then generated from 20 consecutive optical sections. All images were processed using Fiji software.

Immunohistochemistry (IHC) {#s4-6}
--------------------------

IHC was carried out as previously described ([@bib53]) using the following antibodies: anti-L1 (MAB5272, MilliporeSigma), anti-ROBO1 (NBP2-20195, Novus Biologicals), anti-ROBO2 (NBP1-81399, Novus Biologicals), anti-ROBO3 ([@bib47]), anti-TAG1 (4D7, Developmental Studies Hybridoma Bank), and Alexa Fluor 594-conjugated secondary antibodies (Jackson ImmunoResearch). The antibodies were used at a final concentration of 0.5--1 μg/ml.

In ovo electroporation {#s4-7}
----------------------

Culturing of chicken embryos and in ovo electroporation were performed as described previously ([@bib10]). *Actb-gfp* (*βactin-gfp*) and *Robo1/2* expression constructs (in the pCAGGS vector) were microinjected into the neural tube of E3 chicken embryos (stage 18) and electroporated into one half of the spinal cord (ECM830 electroporator, 30 volts, 50 ms/pulse, five pulses). The concentration of the plasmids was 150 ng/μl. After culturing for an additional 48 hr at 37°C (until stage 25), spinal cords were microdissected, fixed with 4% PFA, and imaged in an openbook configuration with fluorescence microscopy. Commissural axons were distinguished from ipsilateral axons as the former turned longitudinally next to the midline while the latter turned at a more dorsolateral position. To assess exogenously expressed mouse ROBO proteins, anti-HA (3F10, Roche) was used to stain transverse sections of chicken spinal cord. In addition, we lysed chicken spinal cords with lysis buffer (10 mM Tris, 150 mM NaCl, 1% Triton X-100, pH 8, with protease inhibitors). After centrifugation to remove undissolved materials, SDS loading buffer (4x with 200 mM Tris-HCl pH6.8, 8% SDS, 0.4% bromophenol blue, 400 mM DTT) was added to the supernatant and the lysate was analyzed by SDS-PAGE using anti-HA conjugated with HRP (Roche).

Whole embryo culture {#s4-8}
--------------------

Whole embryo culture was carried out as previously described ([@bib10]). Embryos were electroporated at E9.75 with *Actb-gfp* (*βactin-gfp*) and cDNAs into one side of the spinal cord and were cultured for 40 hr at 37°C. Spinal cords were microdissected, fixed with 4% PFA, and imaged in an openbook configuration with fluorescence microscopy. We have previously shown that *Actb-gfp* (*βactin-gfp*)-expressing axons are almost exclusively ROBO3-positive commissural axons due to the developmental stage at the time of injection ([@bib40]).

Quantification of phenotypes {#s4-9}
----------------------------

For quantifying midline crossing from DiI labeling, fluorescent axonal signals from the contralateral side were compared to those from the ipsilateral axons, as previously described ([@bib10]). 3--5 DiI injection points were analyzed for each animal. The signals were measured using ImageJ (NIH). For quantifying *gfp*-labeled axon midline crossing, the same measurements were taken and compared, except that areas with cell bodies were avoided to reduce background.

For quantification of axon lateral positioning in chicken embryos, the distance between the dorsolateral-most axons and the midline was compared to the total dorsal-ventral height of the spinal cord (distances 1 and 2 in [Figure 5A](#fig5){ref-type="fig"}, respectively). For quantifying the lateral positioning of anti-L1 or anti-ROBO1 labeled axons, the thickness of the lateral and ventral funiculi were measured using ImageJ, as previously described ([@bib28]). As the number of postcrossing axons was reduced in *Nova1/2* dKO embryos due to fewer axons reaching the midline, we compared the thickness of the lateral and ventral funiculi from the same section (see [Figure 4C](#fig4){ref-type="fig"}). 5--10 sections from each animal were analyzed. As it is difficult to obtain a large number of compound mutants, we used the rostral half of the spinal cord for DiI labeling and the lumbar level for anti-L1 and anti-ROBO1 staining. To reduce variation in developmental stages, littermates of comparable sizes and from more than three litters were examined.

For quantifying the ventral commissure size in [Figures 2A](#fig2){ref-type="fig"} and [7C](#fig7){ref-type="fig"}, the thickness of the commissure was compared to that of the floor plate. Measurements were taken using ImageJ. To minimize developmental variations, we examined animals from at least three different litters, selected embryos of the same size, and used anti-TAG1 patterns to further gauge the developmental stages (see [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). 5--10 spinal cord sections from each animal were quantified.

Quantitative and semi-quantitative RT-PCR {#s4-10}
-----------------------------------------

Spinal cord tissues were microdissected, and the dorsal and ventral halves were separated to distinguish between the commissural and motor neuron populations. Rat tissues were used to examine temporal gene/exon expression due to the ease of microdissection at earlier stages. Total RNA was extracted using Trizol (Thermo Fisher Scientific), and reverse transcription was carried out using Maxima RT (Thermo Fisher Scientific). Quantitative PCR was carried out using a Realplex^2^ thermocycler (Eppendorf). Semi-quantitative PCR was performed to generate multiple isoforms in a single reaction and to compare the relative expression by electrophoresis. The cycle number used in semi-quantitative PCR was determined by quantitative PCR to obtain products during the exponential amplification phase.

  Primers used for quantitative PCR                                                                                                                                                                                                                                              
  ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- --------------------------
  *Robo1*                                                                 E6b-                                                                                                                                                                       gacagttcaagagccgccacattt    gatttccagttgcttcgcactg
                                                                          E6b+                                                                                                                                                                       cgctactttgacagttcaagttggg   gatttccagttgcttcgcactg
                                                                          Common exons                                                                                                                                                               gggatcatacacttgtgtggcagaa   gatttccagttgcttcgcactg
  *Robo2*                                                                 E6b-                                                                                                                                                                       ccctcactgtccgagctcctcc      ttgagcaacgatctgatctcttgg
                                                                          E6b+                                                                                                                                                                       ccgagttcgccctgttgctcc       ttgagcaacgatctgatctcttgg
                                                                          E21-                                                                                                                                                                       ggaacaacggtgggaaaggtgg      ggaggaggaggtaga
                                                                          E21+                                                                                                                                                                       gcaccaccagctctcacaacagc     ggaggaggaggtaga
                                                                          Common exons                                                                                                                                                               agtggaagcctctgctaccctc      ttgagcaacgatctgatctcttgg
  *Nova1*                                                                 Common exons                                                                                                                                                               ctcgcggaaaaggccgcttg        gtactggccgtcttcgcccgt
  *Nova2*                                                                 Common exons                                                                                                                                                               cgacagagccaagcaggcca        acggtcaccacgcgctcttg
  *Hprt*                                                                  Common exons                                                                                                                                                               tgacactggtaaaacaatgca       tcaaatccaacaaagtctg
                                                                                                                                                                                                                                                                                 
  Primers used for semi-quantitative PCR (amplifying multiple isoforms)                                                                                                                                                                                                          
  Gene                                                                    Amplicon                                                                                                                                                                   Forward primer              Reverse primer
  *Robo1*                                                                 Exon 6b                                                                                                                                                                    gggatcatacacttgtgtggcagaa   ctggtcccgaggttttacaacg
                                                                          Exon 18                                                                                                                                                                    gcaagaagagaaacggactcacca    cggcctccctccactgctg
                                                                          Exon 21                                                                                                                                                                    ccatggctggcagacacg          ctggatgagttgagtggtggc
  *Robo2*                                                                 Exon 6b                                                                                                                                                                    agtggaagcctctgctaccctc      ttgagcaacgatctgatctcttgg
                                                                          Exon 21                                                                                                                                                                    ccacagtggaaaagctcagttca     ggaggaggaggtaga
                                                                          Exon 24b                                                                                                                                                                   cccaggcccctcagagcacta       gtgggccgctgcctttgaga
                                                                          Exon 26                                                                                                                                                                    acagccagtgttacctcatcgg      ctgatgagctgtgcccgcca
  *Foxp1*                                                                 Exons 15 to 17 of *Foxp1* with exons 16 and 16b sequences replaced by *Robo1/2* exon 6b (also see below and [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).   gaatgtttgcttacttccgacgc     agtaggcgtggctgctctgc

Splicing assay {#s4-11}
--------------

The total genomic sequence between exons 6 and 7 is 25 kb in *Robo1* and *Robo2*, with candidate NOVA-binding sites located in flanking introns adjacent to exon 6b. We cloned an approximately 500 bp genomic fragment containing exon 6b and the NOVA-binding sites, and inserted it in between *Foxp1* exons 15 and 17 to replace exons 16 and 16b. *Foxp1* exons 15 and 17 are constitutive, whereas exons 16 and 16b are alternatively spliced under the control of *Nova* ([@bib59]). In the exon 6b splicing reporter, *Foxp1* exons 16/16b and the surrounding NOVA-binding sites were deleted and replaced by *Robo1/2* exon 6b and its flanking intron sequences (see [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). The *Foxp1* reporter construct is in the pcDNA3 backbone and was provided by the Darnell group at Rockefeller University. We transfected COS-1 cells with the splicing reporter with TransIT-LT1 (Mirus Bio), together with *Nova1*, *Nova2*, or an empty expression vector. The cells were cultured for 48 hr and the total RNA was collected using Trizol (Thermo Fisher Scientific). Reverse transcription was performed from a BGH reverse primer (5'aaacaacagatggctggcaact3') using SMARTScribe reverse transcriptase (Clontech), and semi-quantitative PCR was performed to amplify splice isoforms. A V5 tag at the C-terminus of NOVA1 and NOVA2 was used to confirm protein expression by western blotting. Point mutations were introduced by PCR reactions using Pfu polymerase (Agilent), and were confirmed by Sanger sequencing.

To generate the *Robo2* exon 21 splicing reporter, we cloned the full genomic DNA between exons 20 and 22 (5.8 kb total) into the pcDNA3.1 vector containing a CMV promoter. Splicing assays with WT and mutant binding sites were performed in the same way as described above.

Small GTPase activation assay {#s4-12}
-----------------------------

COS-1 cells were grown in 24-well plates and transfected in reduced serum medium Opti-MEM (Thermo Fisher Scientific) for 24 hr. Plasmids were used at 100 ng/well for *Robo1/2* and 50 ng/well for *Cdc42/Rac1*. We found that higher amounts of *Robo* cDNA or longer periods of expression can affect CDC42/RAC1 activation in the absence of SLIT2 stimulation. Cells were stimulated with 500 ng/ml mouse SLIT2 N-term (R and D 5444-SL) for 10 min at 37°C, and were lysed on ice for 5 min in 50 mM Tris, pH7.5, 10 mM MgCl~2~, 150 mM NaCl, 2% IGEPAL, and protease inhibitors (Roche). After centrifugation at 14,000 rpm for 5 min at 4°C, 1/10 of the supernatant was kept to detect ROBO1/2 and total CDC42/RAC1. To the rest of the supernatant, EDTA was added at 15 mM and GTPγS at 0.2 mM. After incubation at room temperature for 15 min, MgCl~2~ was added at 60 mM to stop GTPγS loading. PAK-GST beads (Cytoskeleton), which specifically bind GTP-bound CDC42/RAC1, were added and the samples were incubated with rotation at 4°C for 1 hr. After three washes with 50 mM Tris, pH7.5, 30 mM MgCl~2~, and 150 mM NaCl at 4°C, bead-bound proteins were analyzed by western blotting. ROBO1/2 proteins were detected by a C-terminal HA peptide tag (HRP-conjugated anti-HA, 3F10, Roche) and CDC42/RAC1 were detected by a C-terminal FLAG tag (HRP-conjugated anti-FLAG, M2, Sigma Aldrich). To quantify the fold change in CDC42/RAC1 activation, the signal intensity of protein bands was measured using ImageJ. GTP-bound protein was first normalized to the total protein for each condition. The ratio between the normalized signals from before and after SLIT2 stimulation was then calculated as the fold change for each ROBO1/2 isoform. Three independent assays were performed and are illustrated in the graphs in [Figure 6B](#fig6){ref-type="fig"}.

AP-SLIT2/ROBO-binding assay {#s4-13}
---------------------------

AP-SLIT2 was produced by fusing alkaline phosphatase to the N-terminus of human SLIT2. This fusion protein has been previously shown to bind the ROBO receptors ([@bib7]). The fusion protein was produced in HEK293T cells and the protein concentration was determined by measuring the AP activity against an AP protein standard (Colorimetric AP assay kit, Abcam). COS-1 cells were transfected with *Robo1/2* cDNAs and cultured for 24 hr. Binding of AP-SLIT2 was performed using a previously described protocol ([@bib11]). Briefly, AP-SLIT2 proteins were added to the culture medium at a series of concentrations and binding was performed at room temperature for 90 min in the presence of 1 μg/ml heparin. After 3--6 washes in Hank's balance buffer supplemented with 0.5 mg/ml BSA, 20 mM HEPES, and 1 μg/ml heparin, pH 7.4, the cells were lysed (10 mM Tris, 150 mM NaCl, 1% Triton X-100, pH 8, with protease inhibitors). After clearing the lysate by centrifugation, AP substrate, para-nitrophenyl phosphate, was added to the lysate and optical density was measured at 405 nm. Data were analyzed using Prism7 and fitted with one site specific binding with Hill slope method. Three independent binding assays were performed and the level of binding was normalized to the saturating level of signaling.

Cell surface biotinylation assay {#s4-14}
--------------------------------

Biotinylation was performed as described previously ([@bib39]). Briefly, *Robo1/2* cDNAs were transfected into COS-1 cells. At 24 hr post-transfection, the cells were washed with cold 1x PBS (pH 8.0), and biotinylated at 4°C with EZ-Link-Sulfo-NHS-SS-Biotin (Thermo Fisher Scientific) following the manufacturer's protocol. After removing excess reagent and washing the cells with 1xPBS, the cells were lysed (10 mM Tris, 150 mM NaCl, 1% Triton X-100, pH 8, with protease inhibitors). After clearing the lysate by centrifugation, biotinylated cell-surface proteins were pulled down using NeutrAvidin agarose (Thermo Fisher Scientific). Proteins in the total lysate and in the pull-down fraction were analyzed by SDS-PAGE and western blotting.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Alternative splicing of mammalian ROBO1/2 microexons provides temporal regulation of axonal repulsion\" for consideration by *eLife*. Your article has been reviewed by Marianne Bronner as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Grant Mastick (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The three reviewers generally had positive assessments of your study on a new role for the Nova RNA binding proteins in the regulation of Robo receptor alternative splicing during spinal commissural axon guidance. They applauded your efforts to test the function of the poorly understood Robo 1 and 2 isoforms, with strong genetic experiments, expression of altered Robo constructs, and the mechanisms of splicing by the Nova1/2 splicing factors, including the timing of splicing. You show that splicing isoforms have distinct guidance and signaling activities, revealing physiological function of alternatively spliced microexons. Especially interesting is your Crispr-based manipulation of the Robo locus to restore the balance of alternative splicing in the Nova1/2 mutant background results in a significant rescue of the Nova1/2 crossing defects.

Nonetheless, the reviewers call for revision, both additional experimental analysis and textual amendments in the Discussion section:

Essential revisions:

I\) Further analysisa) There was concern that the most significant function of the ex6b is shown in the context of Nova1/2 double knock-outs in which hundreds of other mRNA transcripts are also potentially changed), and that there is no definitive insight into mechanism of how the microexon impacts Robo1/2 function. To confirm that the microexon mutant mice indeed differ from wild-type only in the single microexon, the reviewers encourage you to survey additional splicing events surrounding the deleted exon. You report no changes in exon 21 and 26 -- but generally the concern in such mutants is the unintentional generation of cryptic splice acceptor or donor sites in the mutant transcript in proximity to the mutated region. One question is whether splice isoforms are expressed at comparable levels in your gain of function experiments. Given the subtle nature of the protein coding differences in these Robo isoforms, it is important to demonstrate that they are comparably expressed in the context of the guidance events (not just in heterologous cells).

b\) The reviewers ask you to probe with quantitative methods whether there are any changes in total Robo1/2 mRNAs or proteins in the mutants, because the staining in Figure 4---figure supplement 2 are not quantitative and the other functional experiments involve overexpression, which are difficult to interpret.

Thus, we ask that you to assess RNA and protein levels, as well as splice junctions, in NOVA1/2 DKO mice, to confirm whether the manipulations caused an indirect effect on protein or RNA stability. The outcome could change the interpretation of your results but may also strengthen your conclusions on splice isoforms.

II\) Textual additionsa) Figure 1 shows that Nova1/2 mutants have a clear change in post-crossing trajectories, causing axons to angle away from the midline. While this may reflect changes in Robo-mediated repulsion, the text should consider the possibility that the post-crossing errors caused by Nova1/2 mutations also alter Netrin guidance. A study by Shoja-Taheri, et al., 2015 showed similar post-crossing errors in Netrin1 mutant hindbrain commissural axons, and explant experiments provided support for the retention of post-crossing commissural axon responsiveness to Netrin midline attraction. Given the similarity in axon responses, and your previous evidence of Nova1/2 regulation of Netrin/DCC signaling, the Shoja-Taheri paper should be cited and considered in interpreting the post-crossing trajectories.

b\) Another reviewer request is that the Discussion section would be improved by integrating the Robo1/2 splicing evidence with the other previously identified mechanisms for Robo1/2 regulation. How do you weigh the relative importance of the other levels of regulation, such as receptor localization, interaction with other receptors and other signaling systems, etc. An obvious question to raise is to what extent that the regulatory steps may interact or be dependent on each other: are they hierarchical, or additive? Could the splice isoforms be differentially regulated by receptor trafficking mechanisms, for example?

c). A major issue is the conflict between the present results and those of your previous study -i.e., that both DCC and Robo splicing can rescue the Nova1/2 DKO phenotype. Previous work from your lab has implicated Nova1 and 2 in the control of alternative splicing of the Netrin receptor DCC (2016).

You show that DCC and Nova mutants result in strikingly similar phenotypes with similar severity in terms of midline crossing defects. Rescue experiments indicating that expression of specific Nova-dependent splice variants of DCC can restore midline crossing in Nova mutants, together with a number of in vitro assays, argue that Nova and DCC function together to regulate axon growth across the midline. In the present paper, you begin by showing that Nova1/2, DCC triple mutants have even stronger defects than DCC or Nova alone, suggesting that Nova and DCC act in parallel (Figure 1).

Moreover, why should both over-expressing DCC, and reducing Robo lead to a suppression of the Nova phenotypes? This is particularly puzzling given that in your prior work, you found that in contrast to expression of DCC (which rescues Nova mutants) that expression of Robo3 (which should attenuate Robo repulsion to some degree) has no effect (2016, Figure 8). In contrast, in the current work, you detect trans-heterozygous interactions between Robo3 and the Nova genes that reveal striking LOF phenotypes and suggest that Nova functions with Robo3 (Figure 2).

The reviewers thus urge you to reconcile this apparent disconnect in the Discussion section, especially the new genetic interactions with Robo3, since your previous study argued for the specificity of Nova function with DCC and showed that Robo3 was unable to rescue Nova phenotypes. You should also consider including DCC in your current model in Figure 8.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

The manuscript has been improved and the reviewers thought your amendments were appropriate and sufficient to move forward. They continue to be concerned that the read-outs for phenotypes from dye tracing or antibody labeling to indicate bundle thickness, etc. are semi-quantitative, and that measurements of Robo1/2 mRNA and protein levels are limited by analysis of whole spinal cord rather than relevant cell populations within the spinal cord. In addition, questions remain about the differential action of the 6b+ vs 6b- isoforms. Nonetheless, they feel that the study does highlight a critical function of a micro exon in vivo.

However, there are some remaining issues that need to be addressed before acceptance, as outlined below. As Reviewing Editor, I found that the Abstract, Discussion section and model in Figure 8 need further revision; the revisions listed would make the results more accessible and exhibit your story in the best light.

1\) Your summary of results in the Introduction is very clear: \"Here we report that Robo1/2 alternative splicing at microexon 6b is crucial for axon guidance and is controlled by the NOVA (Neuro-oncological ventral antigen) family of splicing factors.... We show that loss of Nova1/2 alters the expression of exon 6b and leads to severe midline crossing and postcrossing guidance defects. Genetically restoring the expression profile of Robo1/2 exon 6b is able to reverse these defects in Nova mutants. Interestingly, exon 6b alternative isoforms display distinct guidance activities and their production is developmentally regulated. Consequently, ROBO-mediated repulsion is not uniformly repressed precrossing as previously believed, but is instead activated initially to block premature crossing and is sufficiently blocked during crossing.\"

The Abstract, however, is very vague and does not inform the reader on the results. You do not indicate that microexon 6b splice variants of Robo1/2 are controlled by Nova1/2. The abstract should be rewritten to be more precise and reflective of the results.

2\) Likewise, the beginning of the Discussion section should summarize the results more concisely, as in the paragraph at the end of the Introduction. The remainder of the Discussion section wanders and there is a degree of hand-waving. Your findings and the advances they make in the control of DCC-Netrin and Robo-Slit signaling should be stated more clearly.

3\) The model. In Figure 8, though very welcome, is not graphically clear; the reader should be able to glean the results without looking at the legend.

a\) \"Mutant\" should be \"Mutants\", as more than one mutant is included.

b\) 1. and 2. titles should either be put on the midline (so as to refer to both Wildtype and Mutants) or the font should be bigger

c\) Robo1/2 inhibition in red, and \"low repulsion\" are confusing. Put a space between axon under DCC and Robo1/2.

d\) The graphic for Microexon 6b alternative splicing being developmentally controlled is not obvious.

4\) Figure 8 legend is not at all clear; it attempts to compare wildtype and mutant but does not indicate wildtype vs mutant.

a\) For example, Figure 8 legend: \"Nova1/2 regulate (should be \"regulates\") Dcc alternative splicing (of what?), and (should be: \"but in the Nova1/2 dKO\", Nova deficiency reduces Dcc~long~ and causes fewer axons to reach the midline\".

b\) On the right of the diagram under Mutant, as drawn, it is not clear whether premature turning occurs with Robo3 KO or Nova1,2 dKO (when Robo1/2 (e6b+ increases), or whether there might be an interaction between robo3 and Robo1/2 and e6b+.

5\) Text in English. We appreciate that you have utilized an English-speaking colleague to help edit the manuscript. However,

a\) There are still many instances in this revision of inappropriate English usage, as in subsection "Microexon 6b splice variants of ROBO1/2 have distinct guidance activities", Discussion section -- \"Consistently\", should be \"Consistent with these findings...\" or similar.

Figure 5 legend -- \"orientated\" to the left should be \"oriented\".

b\) Throughout, there is incorrect use of singular vs plural.

10.7554/eLife.46042.026

Author response

> Summary:
>
> The three reviewers generally had positive assessments of your study on a new role for the Nova RNA binding proteins in the regulation of Robo receptor alternative splicing during spinal commissural axon guidance. \[...\] Nonetheless, the reviewers call for revision, both additional experimental analysis and textual amendments in the Discussion section:
>
> Essential revisions:
>
> I\) Further analysisa) There was concern that the most significant function of the ex6b is shown in the context of Nova1/2 double knock-outs in which hundreds of other mRNA transcripts are also potentially changed), and that there is no definitive insight into mechanism of how the microexon impacts Robo1/2 function. To confirm that the microexon mutant mice indeed differ from wild-type only in the single microexon, the reviewers encourage you to survey additional splicing events surrounding the deleted exon. You report no changes in exon 21 and 26 -- but generally the concern in such mutants is the unintentional generation of cryptic splice acceptor or donor sites in the mutant transcript in proximity to the mutated region. One question is whether splice isoforms are expressed at comparable levels in your gain of function experiments. Given the subtle nature of the protein coding differences in these Robo isoforms, it is important to demonstrate that they are comparably expressed in the context of the guidance events (not just in heterologous cells).

To survey alternative splicing events surrounding the deleted exon 6b, we performed RT-PCR to amplify the coding sequences between exons 5 and 8, which encode the Ig3 to Ig4 domains. To detect potential sequence changes, we cloned the RT-PCR products and Sanger sequenced 15 individual clones from the mutants. Only one product was detected, which was the e6b- isoform. The results are now included in the text and in Figure 4---figure supplement 1D.

To confirm that *Robo1/2* isoforms are comparably expressed within axons in the gain of function assays, we performed immunohistochemistry on spinal cord sections and found that different isoforms were overexpressed to similar levels and the overexpressed proteins could be detected on both pre- and post-crossing axons. The results are now included in Figure 5C.

> b\) The reviewers ask you to probe with quantitative methods whether there are any changes in total Robo1/2 mRNAs or proteins in the mutants, because the staining in Figure 4---figure supplement 2 are not quantitative and the other functional experiments involve overexpression, which are difficult to interpret.
>
> Thus, we ask that you to assess RNA and protein levels, as well as splice junctions, in NOVA1/2 DKO mice, to confirm whether the manipulations caused an indirect effect on protein or RNA stability. The outcome could change the interpretation of your results but may also strengthen your conclusions on splice isoforms.

Using quantitative RT-PCR and western blotting, we assessed the total mRNA and proteins levels of Robo1/2, respectively, in Nova1/2 dKO. We found that the levels were comparable to those in WT. We also cloned and sequenced the RT-PCR products from exons 5-8 in Nova dKO and confirmed that there was no cryptic splice site being used in Nova dKO. Using quantitative RT-PCR and western blotting, we also examined the total mRNA and protein levels in exon 6b deletion mutants and did not detect any significant changes from WT levels. The results are included in Figure 3---figure supplement 1A,B and in Figure 4---figure supplement 1B,C.

> II\) Textual additionsa) Figure 1 shows that Nova1/2 mutants have a clear change in post-crossing trajectories, causing axons to angle away from the midline. While this may reflect changes in Robo-mediated repulsion, the text should consider the possibility that the post-crossing errors caused by Nova1/2 mutations also alter Netrin guidance. A study by Shoja-Taheri, et al., 2015 showed similar post-crossing errors in Netrin1 mutant hindbrain commissural axons, and explant experiments provided support for the retention of post-crossing commissural axon responsiveness to Netrin midline attraction. Given the similarity in axon responses, and your previous evidence of Nova1/2 regulation of Netrin/DCC signaling, the Shoja-Taheri paper should be cited and considered in interpreting the post-crossing trajectories.

The previous finding by Shoja-Taheri et al., is indeed crucial for our interpretation. The Shoja-Taheri paper shows that Netrin signaling regulates post-crossing projection of commissural axons in the hindbrain, but not in the spinal cord. Our observation in the spinal cord is consistent with these findings. We have modified the text to clarify Netrin's role in the postcrossing errors in Nova1/2 mutants.

> b\) Another reviewer request is that the Discussion section would be improved by integrating the Robo1/2 splicing evidence with the other previously identified mechanisms for Robo1/2 regulation. How do you weigh the relative importance of the other levels of regulation, such as receptor localization, interaction with other receptors and other signaling systems, etc. An obvious question to raise is to what extent that the regulatory steps may interact or be dependent on each other: are they hierarchical, or additive? Could the splice isoforms be differentially regulated by receptor trafficking mechanisms, for example?

We have significantly revised the text. We have discussed how ROBO splice isoforms may be regulated at different levels, such as in trafficking. We have discussed how ROBO isoforms may interact with other signaling pathways. We have also included discussions on the relationship between midline attraction and repulsion and the role of NOVA in both events.

> c\) A major issue is the conflict between the present results and those of your previous study -i.e., that both DCC and Robo splicing can rescue the Nova1/2 DKO phenotype. Previous work from your lab has implicated Nova1 and 2 in the control of alternative splicing of the Netrin receptor DCC (2016).
>
> *You show that DCC and Nova mutants result in strikingly similar phenotypes with similar severity in terms of midline crossing defects. Rescue experiments indicating that expression of specific Nova-dependent splice variants of DCC can restore midline crossing in Nova mutants, together with a number of* in vitro assays, argue that Nova and DCC function together to regulate axon growth across the midline. In the present paper, you begin by showing that Nova1/2, DCC triple mutants have even stronger defects than DCC or Nova alone, suggesting that Nova and DCC act in parallel (Figure 1).
>
> Moreover, why should both over-expressing DCC, and reducing Robo lead to a suppression of the Nova phenotypes? This is particularly puzzling given that in your prior work, you found that in contrast to expression of DCC (which rescues Nova mutants) that expression of Robo3 (which should attenuate Robo repulsion to some degree) has no effect (2016, Figure 8). In contrast, in the current work, you detect trans-heterozygous interactions between Robo3 and the Nova genes that reveal striking LOF phenotypes and suggest that Nova functions with Robo3 (Figure 2).
>
> The reviewers thus urge you to reconcile this apparent disconnect in the Discussion section, especially the new genetic interactions with Robo3, since your previous study argued for the specificity of Nova function with DCC and showed that Robo3 was unable to rescue Nova phenotypes. You should also consider including DCC in your current model in Figure 8.

This is indeed an important issue and we have revised the Results section, the Discussion section and the model in Figure 8 to better demonstrate the relationship between Nova and Dcc, and between Nova and Robo. To briefly summarize the changes here, we have found that the midline crossing defects in Nova1/2 mutants are twofold. One involves the reduction of DCC attraction, which impairs axonal outgrowth and causes fewer axons to reach the midline. The other is blocked crossing by axons that are able to reach the midline, which we show in this study results from elevated ROBO repulsion. In Dcc; Nova1/2 triple KO, both defects are manifested, in that Dcc KO blocks axons from reaching the midline (Nova1/2 dKO is loss of function but not completely null in this aspect), and elevated ROBO in Nova1/2 dKO blocks half of the axons at the midline from entering. We previously showed that restoring DCC~long~ expression in Nova mutants is able to rescue axonal outgrowth and axonal attraction toward the midline (i.e. we quantified the amount of axons that were able to arrive at the midline in 2016). Here, we further show that restoring Robo isoform expression, by reducing e6b+ levels, enables midline entry within axons that are able to reach the midline. By contrast, overexpressing Robo3.1, which represses elevated Robo repulsion, is not sufficient to restore axonal outgrowth and attraction toward the midline (2016). Instead, Robo3 and Nova1/2 have a synergistic interaction in allowing midline entry, as both groups of genes downregulate ROBO activity. We also considered the possibilities that elevated ROBO repulsion can reduce the amount of axons reaching the midline and that dampened DCC attraction can block crossing. Given that projecting toward the midline can be restored by DCC isoform expression and that blocked crossing can be largely rescued by restoring Robo isoform expression, the alternative scenarios are unlikely to make major contributions.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> *The manuscript has been improved and the reviewers thought your amendments were appropriate and sufficient to move forward. They continue to be concerned that the read-outs for phenotypes from dye tracing or antibody labeling to indicate bundle thickness, etc. are semi-quantitative, and that measurements of Robo1/2 mRNA and protein levels are limited by analysis of whole spinal cord rather than relevant cell populations within the spinal cord. In addition, questions remain about the differential action of the 6b+ vs 6b- isoforms. Nonetheless, they feel that the study does highlight a critical function of a micro exon* in vivo.
>
> However, there are some remaining issues that need to be addressed before acceptance, as outlined below. As Reviewing Editor, I found that the Abstract, Discussion section and model in Figure 8 need further revision; the revisions listed would make the results more accessible and exhibit your story in the best light.
>
> 1\) Your summary of results in the Introduction is very clear: \"Here we report that Robo1/2 alternative splicing at microexon 6b is crucial for axon guidance and is controlled by the NOVA (Neuro-oncological ventral antigen) family of splicing factors.... We show that loss of Nova1/2 alters the expression of exon 6b and leads to severe midline crossing and postcrossing guidance defects. Genetically restoring the expression profile of Robo1/2 exon 6b is able to reverse these defects in Nova mutants. Interestingly, exon 6b alternative isoforms display distinct guidance activities and their production is developmentally regulated. Consequently, ROBO-mediated repulsion is not uniformly repressed precrossing as previously believed, but is instead activated initially to block premature crossing and is sufficiently blocked during crossing.\"
>
> The Abstract, however, is very vague and does not inform the reader on the results. You do not indicate that microexon 6b splice variants of Robo1/2 are controlled by Nova1/2. The abstract should be rewritten to be more precise and reflective of the results.

We have rewritten the Abstract to summarize our results more precisely.

> 2\) Likewise, the beginning of the Discussion section should summarize the results more concisely, as in the paragraph at the end of the Introduction. The remainder of the Discussion section wanders and there is a degree of hand-waving. Your findings and the advances they make in the control of DCC-Netrin and Robo-Slit signaling should be stated more clearly.

We have rewritten the beginning of the Discussion section to better summarize the significance of our findings. We have removed one paragraph from the end of the Discussion section to make the text more focused.

> 3\) The model. In Figure 8, though very welcome, is not graphically clear; the reader should be able to glean the results without looking at the legend.
>
> a\) \"Mutant\" should be \"Mutants\", as more than one mutant is included.
>
> b\) 1. and 2. titles should either be put on the midline (so as to refer to both Wildtype and Mutants) or the font should be bigger
>
> c\) Robo1/2 inhibition in red, and \"low repulsion\" are confusing. Put a space between axon under DCC and Robo1/2.
>
> d\) The graphic for Microexon 6b alternative splicing being developmentally controlled is not obvious.

We have modified the Figure to address all the issues listed above.

> 4). Figure 8 legend is not at all clear; it attempts to compare wildtype and mutant but does not indicate wildtype vs mutant.
>
> a\) For example, Figure 8 legend: \"Nova1/2 regulate (should be \"regulates\") Dcc alternative splicing (of what?), and (should be: \"but in the Nova1/2 dKO\", Nova deficiency reduces Dcc~long~ and causes fewer axons to reach the midline\".
>
> b\) On the right of the diagram under Mutant, as drawn, it is not clear whether premature turning occurs with Robo3 KO or Nova1,2 dKO (when Robo1/2 (e6b+ increases), or whether there might be an interaction between robo3 and Robo1/2 and e6b+.

We have modified the figure legend to better compare the WT and the mutants. In the text, we use Nova1/2 to refer to both Nova1 and Nova2. We realized this is unclear to the readers, and we have clarified this point at the beginning of the Introduction.

> 5\) Text in English. We appreciate that you have utilized an English-speaking colleague to help edit the manuscript. However,
>
> a\) There are still many instances in this revision of inappropriate English usage, as in subsection "Microexon 6b splice variants of ROBO1/2 have distinct guidance activities", Discussion section -- \"Consistently\", should be \"Consistent with these findings...\" or similar
>
> Figure 5 legend -- \"orientated\" to the left should be \"oriented\".
>
> b\) Throughout, there is incorrect use of singular vs plural.

We have corrected the mistakes listed above. In addition, we have had Heidi Chial, a Writing Specialist from BioMed Bridge, edit our manuscript.

[^1]: ArcherDx, Boulder, United States.

[^2]: Department of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, United States.
